The DOI matches its Crossref record.
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses
Open accessAbstract
Adenoviruses are robust gene delivery vectors in vivo, but are limited by their propensity to provoke strong innate and adaptive responses. Previous work has demonstrated that polyethylene glycol (PEG) modification of adenovirus can protect the vectors from preexisting and adaptive immune responses by reducing protein-protein interactions. To test whether PEGylation can reduce innate immune responses to adenovirus by reducing their interactions with immune cells, first-generation (FG-Ad) and helper-dependent (HD-Ad) Ad5 vectors were PEGylated with SPA-PEG and tested in vitro and in vivo. We demonstrate that increasing PEGylation ablated in vitro transduction, but surprisingly had no negative effect on the level or distribution of in vivo gene delivery. This poor in vitro transduction could be rescued in part by physically forcing the PEGylated vectors onto cells, suggesting that physiological forces in vivo may enable transduction via heparin sulfate proteoglycan and integrin interactions. While transduction remained the same as for unmodified vectors, the PEGylated vectors reduced innate IL-6 responses by 70 and 50% in vivo for FG-Ad and HD-Ad. These reduced innate responses paralleled similar reductions in vector uptake by macrophages in vitro and Kupffer cells in vivo. These data suggest that PEGylation of Ad vectors can reduce innate immune responses without reducing transduction in vivo. These data also suggest that nonspecific vector uptake by macrophages and Kupffer cells may be critically involved in the initial activation of innate immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 31
- Schnell, 2001, Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors, Mol. Ther., 3, 708, 10.1006/mthe.2001.0330 · DOI · Paper page
- Ben-Gary, 2002, Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes, Mol. Ther., 6, 287, 10.1006/mthe.2002.0658 · doi:10.1006/mthe.2002.0658
- Juillard, 1995, Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector, Eur. J. Immunol., 25, 3467, 10.1002/eji.1830251239 · DOI
- Hemminki, 2002, Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy, Hum. Gene Ther., 13, 1505, 10.1089/10430340260185139 · doi:10.1089/10430340260185139
- Vlachaki, 2002, Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model, Mol. Ther., 6, 342, 10.1006/mthe.2002.0669 · DOI
- Varnavski, 2002, Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity, J. Virol., 76, 5711, 10.1128/JVI.76.11.5711-5719.2002 · DOI
- Vilquin, 1995, FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer, Hum. Gene Ther., 6, 1391, 10.1089/hum.1995.6.11-1391 · DOI · Paper page
- Morsy, 1998, An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene, Proc. Natl. Acad. Sci. USA, 95, 7866, 10.1073/pnas.95.14.7866 · DOI · Paper page
- Morral, 1999, Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons, Proc. Natl. Acad. Sci. USA, 96, 12816, 10.1073/pnas.96.22.12816 · DOI · Paper page
- Muruve, 2004, Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo, J. Virol., 78, 5966, 10.1128/JVI.78.11.5966-5972.2004 · DOI · Paper page
- Brunetti-Pierri, 2004, Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates, Hum. Gene Ther., 15, 35, 10.1089/10430340460732445 · DOI · Paper page
- O’Riordan, 1999, PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo, Hum. Gene Ther., 10, 1349, 10.1089/10430349950018021 · DOI · Paper page
- Croyle, 2000, Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions, Hum. Gene Ther., 11, 1713, 10.1089/10430340050111368 · DOI
- Croyle, 2001, “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung, J. Virol., 75, 4792, 10.1128/JVI.75.10.4792-4801.2001 · DOI · Paper page
- Alemany, 2000, Blood clearance rates of adenovirus type 5 in mice, J. Gen. Virol., 81, 2605, 10.1099/0022-1317-81-11-2605 · DOI · Paper page
- Beekman, 1997, Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity, J. Pept. Res., 50, 357, 10.1111/j.1399-3011.1997.tb01195.x · doi:10.1111/j.1399-3011.1997.tb01195.x
- Palmer, 2003, Improved system for helper-dependent adenoviral vector production, Mol. Ther., 8, 846, 10.1016/j.ymthe.2003.08.014 · DOI · Paper page
- Smith, 2003, Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice, Hum. Gene Ther., 14, 777, 10.1089/104303403765255165 · DOI · Paper page
- Ogawara, 2004, A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo, Hum. Gene Ther., 15, 433, 10.1089/10430340460745766 · DOI
- Nakata, 1967, Microcirculation and hemodynamic analysis of the blood circulation of the liver, Acta Pathol. Jpn., 17, 361
- Plank, 2003, The magnetofection method: using magnetic force to enhance gene delivery, Biol. Chem., 384, 737, 10.1515/BC.2003.082 · DOI · Paper page
- Campos, 2004, Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector, Mol. Ther., 9, 942, 10.1016/j.ymthe.2004.03.006 · DOI
- Zsengeller, 1998, Adenovirus-mediated granulocyte–macrophage colony-stimulating factor improves lung pathology of pulmonary alveolar proteinosis in granulocyte–macrophage colony-stimulating factor-deficient mice, Hum. Gene Ther., 9, 2101, 10.1089/hum.1998.9.14-2101 · DOI
- Higginbotham, 2002, The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid, Hum. Gene Ther., 13, 129, 10.1089/10430340152712683 · DOI
- Alemany, 2001, CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors, Gene Ther., 8, 1347, 10.1038/sj.gt.3301515 · DOI · Paper page
- Everett, 2003, Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors, Hum. Gene Ther., 14, 1715, 10.1089/104303403322611737 · DOI
- Martin, 2003, Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism, Mol. Ther., 8, 485, 10.1016/S1525-0016(03)00182-5 · DOI
- Muruve, 1999, Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo, Hum. Gene Ther., 10, 965, 10.1089/10430349950018364 · DOI · Paper page
- Borgland, 2000, Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB, J. Virol., 74, 3941, 10.1128/JVI.74.9.3941-3947.2000 · DOI
- Liu, 2003, Molecular basis of the inflammatory response to adenovirus vectors, Gene Ther., 10, 935, 10.1038/sj.gt.3302036 · DOI · Paper page
- Davis, 2001, Construction of adenoviral vectors, Mol. Biotechnol., 18, 63, 10.1385/MB:18:1:63 · DOI
Cited by
Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting
Campos, S., & Barry, M. (2007) · Current Gene Therapy · doi:10.2174/156652307780859062 · Cited by 210
Self-citationAdenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
Adenoviruses as gene/vaccine delivery vectors: Promises and pitfalls
Appaiahgari, M. B., & Vrati, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.993374 · Cited by 110
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
Utility of PEGylated recombinant adeno-associated viruses for gene transfer
Le, H. T., Yu, Q.-C., Wilson, J. M., & Croyle, M. A. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.019 · Cited by 82
Metadata
- Authors
- Mok, H., Palmer, D. J., Ng, P., & Barry, M. A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2005-01
- Volume
- 11
- Issue
- 1
- Pages
- 66-79
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2022429082
- Cited by
- 232
- References
- 0
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 4297 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. https://app.cochat.ai/papers/10.1016/j.ymthe.2004.09.015
- The paper
- Mok, H., Palmer, D. J., Ng, P., & Barry, M. A. (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2004.09.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.